Devicemakers Testify in Support of Coverage of Breakthrough Technologies at House Hearing

Enabling more rapid Medicare coverage of medical technology innovations through support of CMS’s proposed Transitional Coverage for Emerging Technologies (TCET) was the goal of several devicemakers who spoke in support of the proposal at a recent House Energy and Commerce Health Subcommittee meeting.

CMS proposed TCET two years after it repealed a similar rule that would have expedited Medicare coverage for FDA-cleared Breakthrough Devices.

The hearing, “Innovation Saves Lives: Evaluating Medicare Coverage Pathways for Innovative Drugs, Medical Devices, and Technology”, included testimony from AdvaMed Board member Lishan Aklog, chairman and CEO of PAVMed and Lucid Diagnostics; Todd Brinton, chief scientific officer of Edwards Lifesciences; and Scott Whitaker, AdvaMed president and CEO.

To read the full story, click here to subscribe.

Related Topics